Form 4: IRWD CFO Sells Shares for Tax Obligations
Insider Transaction Report
Ironwood Pharmaceuticals' CFO, Gregory S. Martini, sold 1,265 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Gregory S. Martini, Chief Financial Officer of Ironwood Pharmaceuticals, Inc. (IRWD), reported a sale of company stock.
- The transaction involved 1,265 shares of Class A Common Stock.
- The shares were sold at a price of $0.84 per share.
- Following this transaction, Martini directly owns 182,545 shares of Class A Common Stock.
- The sale was non-discretionary, executed automatically to satisfy tax withholding obligations from restricted stock unit vesting.
Sentiment
Score: 5
Explanation: The transaction is a non-discretionary sale to cover tax obligations from RSU vesting, which is a routine event and does not indicate positive or negative sentiment towards the company's prospects.
Future Outlook
NA
Management Comments
- The sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.
Industry Context
This transaction is a routine insider filing for tax purposes and does not reflect broader industry trends or competitive positioning within the pharmaceutical sector.
Stakeholder Impact
- Minimal impact on shareholders as it is a routine, non-discretionary tax-related sale by an executive.
Key Dates
| Date | Description |
|---|---|
| 08/11/2025 | Date of earliest transaction (sale of Class A Common Stock) |
| 08/12/2025 | Date Power of Attorney was executed by Gregory S. Martini |
| 08/13/2025 | Signature date of the Form 4 filing |
Recommendation
holdThe reported sale by the CFO is a non-discretionary transaction to cover tax withholding obligations associated with restricted stock unit vesting. This is a common and expected event for executives and does not reflect a change in the company's fundamentals or the CFO's outlook on the company's future. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Ironwood Pharmaceuticals, IRWD, Form 4, Insider Transaction, Stock Sale, CFO, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.